A Study of Ivonescimab in Combination With DatoDXd or Osimertinib in People With Non-Small Cell Lung Cancer

Full Title

A Phase 1/2 Trial of Ivonescimab with Dato-DXd or Osimertinib in Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer that Progressed on EGFR TKI Therapy

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Helena Yu’s office at 646-608-3912.

Protocol

25-366

Phase

Phase I/II (phases 1 and 2 combined)

Disease Status

Relapsed or Refractory

Investigator

Helena A. Yu

Co-Investigators

Gregory J. Riely

Diseases

Lung Cancer › Lung Cancer, Non-Small Cell

Locations

Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau

ClinicalTrials.gov ID

NCT07535437

ClinicalTrials.gov

Visit ClinicalTrials.gov for full clinical trial description